Drug Approval | May 12, 2023
USFDA approves GSK’s respiratory syncytial virus vaccine ‘Arexvy’
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
The blood test market worldwide is today around $75-80 billion
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Subscribe To Our Newsletter & Stay Updated
